References
  1. Capoluongo, E.D., Amato, F., Castaldo, G. (2020). The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clin Chem Lab Med . 2020 Clin Chem Lab Med, 2020 Apr 24:/j/cclm.ahead-of-print/cclm-2020-0442/cclm-2020-0442.xml
  2. Tang, N., Bai, H., Chen, X., Gong, J., Li, D., Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost , 2020;18(5):1094-1099.
  3. Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., Clark, C., Iba, T. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Hemost , 18(5):1023-1026
  4. Chan, K.W., Wong, V.T., Tang, S.C.W. (2020). COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J Chin Med , 48(3):737-762.
  5. Berger, N.A., Besson, V.C., Boulares, A.H., et al .(2018). Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol;175:192-222.
  6. Capoluongo, E. (2016). BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet , 1:S1-2;
  7. Mathews, M.T., Berk, B.C.(2008). PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol ,28:711-717